Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1)

Steroids

Volumn 76, Issue 5, 2011, Pages 484-490

  Chen, Mo ^a   Drury, Jason E ^a,b   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bile acids; Non steroidal anti inflammatory drugs; Steroid hormones; Substrate inhibition

Indexed keywords

4 BENZOYLBENZOIC ACID; 4 CHOLESTEN 7ALPHA OL 3 ONE; ALDOSTERONE; ANDROSTENEDIONE; BENZOIC ACID DERIVATIVE; BOLDENONE; CHENODEOXYCHOLIC ACID; CHOLEST 4 EN 3 ONE; CORTICOSTERONE; CORTISONE; EPITESTOSTERONE; HORMONE; HYDROCORTISONE; INDOMETACIN; MEFENAMIC ACID; NANDROLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE INHIBITOR; OXOSTEROID; RECOMBINANT ENZYME; STEROID 5BETA REDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STABILITY; METABOLITE; PH; STRUCTURE ACTIVITY RELATION;

BILE ACIDS AND SALTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN-ION CONCENTRATION; KETOSTEROIDS; KINETICS; OXIDOREDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 79952575594     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.01.003     Document Type: Article

References (35)

1. Russell DW, Setchell KDR. Bile acid biosynthesis. Biochemistry 1992;31:4737-49.
2. Granick S, Kappas A. Steroid control of porphyrin and heme biosynthesis: a new biological function of steroid hormone metabolites. Proc Natl Acad Sci U S A 1967;57:1463-7.
3. Levere RD, Kappas A, Granick S. Stimulation of hemoglobin synthesis in chick blastoderms by certain 5β-androstane and 5β-pregnane steroids. Proc Natl Acad Sci U S A 1967;58:985-90.
4. Sheehan PM, Rice GE, Moses EK, Brennecke SP. 5β-Dihydroprogesterone and steroid 5β-reductase decrease in association with human parturition at term. Mol Hum Reprod 2005;11:495-501. (Pubitemid 41258236)
5. Bertilsson G, Heidrich J, Svensson K, Åsman M, Jendeberg L, Sydow-Bäckman M, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998;95:12208-13. (Pubitemid 28483744)
6. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275:15122-7. (Pubitemid 30337234)
7. Wilson JD. Disorder of androgen action. Clin Res 1987;35:1-12.
8. McInnes KJ, Kenyon CJ, Chapman KE, Livingstone DEW, Macdonald LJ, Walker BR, et al. 5α-Reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor. J Biol Chem 2004;279:22908-12. (Pubitemid 38685592)
9. Penning TM, Drury JE. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007;464:241-50. (Pubitemid 47214569)
10. Gavidia I, Tarrío R, Rodríguez-Trelles F, Pérez-Bermúdez P, Ulrich Seitz H. Plant progesterone 5β-reductase is not homologous to the animal enzyme. Molecular evolutionary characterization of P5βR from Digitalis purpurea. Phytochemistry 2007;68:853-64.
11. 4-3-ketosteroid 5β-reductase and a 3α-hydroxysteroid dehydrogenase. Eur J Biochem 1967;2:493-502.
12. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 1997;326:625-36. (Pubitemid 27438032)
13. 4-3-ketosteroid 5β-reductase (AKR1D1) and implications for substrate binding and catalysis. J Biol Chem 2008;283:16830-9.
14. Drury JE, Di Costanzo L, Penning TM, Christianson DW. Inhibition of human steroid 5β-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J Biol Chem 2009;284:19786-90.
15. 4-3-ketosteroid 5β-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry 2008;47:13537-46.
16. 4-3-ketosteroid 5β-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. Biochemistry 2008;47:8261-70.
17. Schlegel BP, Jez JM, Penning TM. Mutagenesis of 3α-hydroxysteroid dehydrogenase reveals a "Push-Pull" mechanism for proton transfer in aldo-keto reductase. Biochemistry 1998;37:3538-48.
18. + bound to 3α-hydroxysteroid/dihydrodiol dehydrogenase. Structure 1997;5:799-812.
19. Jez JM, Penning TM. Engineering steroid 5β-reductase activity into rat liver 3α-hydroxysteroid dehydrogenase. Biochemistry 1998;37:9695-703. (Pubitemid 28319614)
20. 4-3-oxosteroid 5β-reductase and substrate specificity of the expressed enzyme. Eur J Biochem 1994;219:357-63.
21. Charbonneau A, Luu-The V. Genomic organization of a human 5β-reductase and its pseudogene and substrate selectivity of the expressed enzyme. BBA-Gene Struct Expr 2001;1517:228-35. (Pubitemid 32126520)
22. 4-5β-reductase and dihydrocortisol-3α-oxidoreductase(s). Steroids 1990;55:495-500.
23. Jin Y, Penning TM. Multiple steps determine the overall rate of the reduction of 5α-dihydrotestosterone catalyzed by human type 3 3α-hydroxysteroid dehydrogenase: implications for the elimination of androgens. Biochemistry 2006;45:13054-63. (Pubitemid 44763428)
24. Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 1969;185:269-86.
25. Jez JM, Schlegel BP, Penning TM. Characterization of the substrate binding site in rat liver 3α-hydroxysteroid/dihydrodiol dehydrogenase. J Biol Chem 1996;271:30190-8.
26. Cooper WC, Jin Y, Penning TM. Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate. J Biol Chem 2007;282:33484-93. (Pubitemid 350159515)
27. Grimshaw CE, Bohren KM, Lai C-J, Gabbay KH. Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild-type enzyme. Biochemistry 1995;34:14356-65.
28. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, Penning TM. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 2005;67:60-8. (Pubitemid 40069966)
29. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75:484-93. (Pubitemid 350298472)
30. McNeilly AD, Macfarlane DP, O'Flaherty E, Livingstone DE, Mitić T, McConnell KM, et al. Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice. J Hepatol 2010;52:705-11.
31. 4-3-oxosteroid 5β-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 2008;73:417-23.
32. Heredia VV, Penning TM. Dissection of the physiological interconversion of 5α-DHT and 3α-Diol by rat 3α-HSD via transient kinetics shows that the chemical step is rate-determining: effect of mutating cofactor and substrate-binding pocket residues on catalysis. Biochemistry 2004;43:12028-37. (Pubitemid 39280548)
33. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA. Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 2004;64:1802-10. (Pubitemid 38428705)
34. + retention. Steroids 1994;59:352-6.
35. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 1992;257:81-4.